Biotech Secures Major FDA Orphan Drug Designation for Diabetes Treatment

1. Sernova Biotherapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Biotherapeutics Inc.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Leading regenerative medicine company Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for autologous islet transplantation (AIT) for preventing diabetes following a total pancreatectomy, according to a June 17 release.

This designation is a significant step for Sernova, which is known for developing its Cell Pouch Bio-hybrid Organ aimed at offering a functional cure for type 1 diabetes.

Sernova's Cell Pouch system is engineered to support the engraftment and sustained functionality of transplanted therapeutic cells, the company said. Chronic pancreatitis, which can necessitate a total pancreatectomy, often leads to the development of type 3c diabetes (T3cD). This form of diabetes is managed similarly to type 1 diabetes and is associated with similar long-term health complications. Sernova is gearing up to begin a clinical trial that will utilize autologous islet transplantation. This process involves isolating a patient's own insulin-producing islet cells from their removed pancreas and embedding these cells into the vascularized Cell Pouch Bio-hybrid organ in the patient. This innovative approach aims to preserve insulin production and prevent the onset of diabetes after surgery, thereby eliminating the need for immune suppression and reducing the complexity of managing the disease post-operation.

Dr. Melena Bellin, MD, Co-Director of the Total Pancreatectomy and Islet Autotransplant Program at the University of Minnesota and a member of Sernova's Clinical Advisory Board, highlighted the transformative potential of this treatment.

"Patients who require total pancreatectomy face a life-changing outcome: the immediate loss of pancreatic endocrine function and the risk of complex, insulin-dependent diabetes," she said. "Autologous islet transplantation in Sernova's Cell Pouch has the potential to preserve a patient's own insulin-producing cells following pancreatic surgery, without the use of immune-suppressing therapies."

The Orphan Drug Designation by the FDA is intended to facilitate the development of treatments for rare diseases or conditions affecting fewer than 200,000 people in the United States. This designation offers Sernova various development incentives, including seven years of market exclusivity in the U.S. upon regulatory approval, potential tax credits for clinical testing, and a waiver of certain FDA user fees if applicable criteria are met.

"Receiving Orphan Drug Designation from the FDA is an important milestone for Sernova," Sernova Chief Executive Officer Jonathan Rigby said. "Our primary focus remains advancing a functional cure for type 1 diabetes. At the same time, this designation provides Sernova a potential exclusive lead position in preventing type 3c diabetes. T3cD is a natural extension of our primary focus on T1D, and we are planning to advance."

Capital Structure 'Significantly Improved'

Earlier this year, Sernova announced it had completed financing transactions totaling CA$7.1 million, which significantly enhanced the company's financial stability. The financing included several key transactions, including a CA$1.6 million equity financing through a non-brokered private placement priced at 15 cents per unit. Additionally, the company secured a CA$1.5 million convertible debenture financing from an insider/director. This debenture, bearing a 10% annual interest rate and convertible at 15 cents per share, came with 10 million warrants exercisable at 25 cents for 36 months, pending approval from the Toronto Stock Exchange.

Moreover, a significant CA$4 million equity financing from an insider/director involved 26,666,667 units priced at 15 cents each. The funds were designated to retire the company's existing CA$4 million secured term loan.

In total, including about CA$900,000 raised in a non-brokered private placement in November 2025, Sernova has accumulated over CA$4 million in private placement financings in the past five months. This has substantially improved its capital structure and liquidity profile.

"Over the past year, we have taken decisive steps to stabilize and strengthen our foundation from a financial, management, and board perspective," Rigby said at the time. "With these financings plus the expected net retirement of approximately CA$17 million of debt upon shareholder approval at our AGM, we believe Sernova is entering a period of renewed financial health. Our capital structure is significantly improved, our liquidity position is strengthened, and we remain focused on advancing our clinical programs toward delivering a functional cure for Type 1 diabetes."

A Top Company Developing Diabetes Cell Therapy Treatments

In a June 2 list of "Top Companies Developing Cell Therapy Treatments for Diabetes in 2026," BioInformant Founder and President Cade Hildreth put Sernova at number 5.

"In September 2015, Sernova … secured exclusive worldwide rights to patent-pending technologies developed by researchers at the University Health Network (UHN) in Canada, with the license giving them the capacity to turn stem cells into glucose-responsive therapeutic cells for use in the treatment of insulin-dependent diabetes," Hildreth noted.

In January 2016, Sernova announced a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to "establish, optimize and validate Sernova's licensed technology for creating stem cell-derived therapeutic cells that produce insulin and are glucose responsive," Hildreth wrote.

According to an AI analysis of the stock by StockInvest.us, on June 16, the stock was positioned at the lower end of a broad and declining trend in the short term, which might typically suggest a good buying opportunity. However, if the stock breaks through the lower trend floor at CA$0.136, it could indicate a more significant rate of decline. Based on the current trend, the stock is projected to decrease by 9.43% over the next three months, potentially stabilizing between CA$0.123 and CA$0.157 by the end of this period.

The stock has received a buy signal from the three-month Moving Average Convergence Divergence (MACD).

Despite the increase in volume on the last trading day, the decline in prices suggests caution, a scenario often referred to as divergence in technical terms. This could be seen as a positive sign in typical "sell-offs," but the very low volume heightens the risk and diminishes the reliability of other technical signals.

The Catalyst: Diabetes Continues to Be a Major Global Health Issue

The global diabetes drugs market is poised for substantial growth, with its valuation expected to rise from US$101.48 billion in 2025 to US$116.11 billion in 2026, and further surge to US$283.36 billion by 2034. This growth trajectory represents a compound annual growth rate (CAGR) of 11.80% over the forecast period, as reported by Fortune Business Insights. North America is currently at the forefront of this market, claiming a 49.95% share in 2025, with leading companies such as Novo Nordisk A/S, Eli Lilly & Company, and Sanofi spearheading the market.

Diabetes continues to be a major global health concern, affecting an increasing number of people worldwide. According to the International Diabetes Federation (IDF), the number of adults living with diabetes was 537 million in 2021, and this figure is projected to rise to 643 million by 2030 and 783 million by 2045. The disease is not only a significant public health issue but also contributes to a considerable economic burden due to its associated complications and impact on quality of life and lifespan.

The expansion of the diabetes drugs market is primarily driven by the rising prevalence of diabetes, an aging global population, and advancements in drug delivery technologies. A variety of medications are currently available to manage and treat both type 1 and type 2 diabetes mellitus, which aim to reduce blood glucose levels. These include insulin therapies, GLP-1 agonists, and SGLT2 inhibitors, administered through oral, intravenous, or subcutaneous routes.

According to iHealthcareAnalyst, "The disease burden related to diabetes is high and rising in every country, fueled by the global rise in the prevalence of obesity and unhealthy lifestyles."

In North America, diabetes remains a leading cause of death, prompting ongoing research and development of new drugs to provide more effective treatment options for this increasingly common and progressive disease, as noted by Precedence Research.

Non-insulin treatments, particularly favored for initial therapy in type 2 diabetes patients, now constitute over half of the anti-diabetic market. Over the past decade, significant advancements have been made with the introduction of two major classes of drugs: DPP-4 inhibitors and sodium-glucose cotransporter-2 inhibitors (SGLT-2). Oral diabetes medications work in various ways, such as stimulating the pancreas to produce more insulin, enhancing the body's response to insulin, inhibiting glucose production in the liver, or slowing down glucose absorption after meals. Notably, the FDA approved Semaglutide in June 2021 as an adjunct to diet and exercise for obesity treatment, and while Dulaglutide and Exenatide have not received FDA approval for obesity treatment, they are effectively used for weight loss in clinical settings.

Ownership and Share Structure¹

About 13% of the company is held by insiders and management, and less than 1% by institutions. The rest is retail.

Top shareholders include Director Steven Sangha with 13.16%, Chief Financial Officer James Parsons with 0.16%, CATAM Asset Management AG with 0.04%, and Chief Business Officer Modestus Obochi with 0.01%.

Sernova has 377.64 million outstanding shares. Its market cap is CA$52.89 million. Its 52-week range is CA$0.12−CA$0.21 per share.